HC Wainwright disclosed Cara Therapeutics Inc (NASDAQ:CARA), boosting its price target to $20.00 earlier today
- Updated: October 15, 2016
Stating a possible upside of 1.65%, HC Wainwright raised the target price of Cara Therapeutics Inc (NASDAQ:CARA) to $20.00
Previously on 08/08/2016, Needham released a statement about Cara Therapeutics Inc (NASDAQ:CARA) reduced the target price from $27.00 to $23.00. At the time, this indicated a possible upside of 2.92%.
Just yesterday Cara Therapeutics Inc (NASDAQ:CARA) traded -4.20% lower at $7.56. Cara Therapeutics Inc’s 50-day moving average is $7.13 and its 200-day moving average is $6.21. The last stock price is up 24.83% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,798,740 shares of CARA traded hands, up from an average trading volume of 1,049,480
Recent Performance Chart
Cara Therapeutics Inc has 52 week low of $4.26 and a 52 week high of $18.12 and has a market capitalization of $0.
Brief Synopsis On Cara Therapeutics Inc (NASDAQ:CARA)
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body's peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company's I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.